ImmuCell Balance Sheet Health
Financial Health criteria checks 6/6
ImmuCell has a total shareholder equity of $31.4M and total debt of $8.3M, which brings its debt-to-equity ratio to 26.5%. Its total assets and total liabilities are $46.6M and $15.3M respectively. ImmuCell's EBIT is $4.7M making its interest coverage ratio 18.4. It has cash and short-term investments of $8.9M.
Key information
26.46%
Debt to equity ratio
US$8.30m
Debt
| Interest coverage ratio | 18.4x |
| Cash | US$8.86m |
| Equity | US$31.37m |
| Total liabilities | US$15.26m |
| Total assets | US$46.63m |
Recent financial health updates
These 4 Measures Indicate That ImmuCell (NASDAQ:ICCC) Is Using Debt Reasonably Well
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...We Think ImmuCell (NASDAQ:ICCC) Can Stay On Top Of Its Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...ImmuCell (NASDAQ:ICCC) Is Making Moderate Use Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Health Check: How Prudently Does ImmuCell (NASDAQ:ICCC) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...Is ImmuCell (NASDAQ:ICCC) Using Too Much Debt?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Recent updates
Financial Position Analysis
Short Term Liabilities: ICCC's short term assets ($21.1M) exceed its short term liabilities ($4.4M).
Long Term Liabilities: ICCC's short term assets ($21.1M) exceed its long term liabilities ($10.8M).
Debt to Equity History and Analysis
Debt Level: ICCC has more cash than its total debt.
Reducing Debt: ICCC's debt to equity ratio has reduced from 28.3% to 26.5% over the past 5 years.
Debt Coverage: ICCC's debt is well covered by operating cash flow (71%).
Interest Coverage: ICCC's interest payments on its debt are well covered by EBIT (18.4x coverage).
Balance Sheet
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/13 01:14 |
| End of Day Share Price | 2026/09/11 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ImmuCell Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Nathan Weinstein | Aegis Capital Corporation |